Advanz Pharma
acquired/legacy branded and specialty pharmaceuticals
Privately held: no public share price · United Kingdom
Assets
(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | 5-HT1D receptorSmall molecule | Migraine | |
| Approved | Autophagy/lysosomal acidificationSmall molecule | Systemic Lupus ErythematosusRheumatoid Arthritis | |
| Approved | Voltage-gated sodium channelsSmall molecule | Epilepsy | |
| Preclinical / Unstaged | VEGF-AProtein / enzyme therapeutic | Age-Related Macular Degeneration |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.